Opioid Overdose
📧 Sign up to get email alerts when something new happens for Opioid Overdose.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-08-21FDA Approved: NALOXONE HYDROCHLORIDE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approves Meitheal Pharmaceuticals' naloxone hydrochloride as a generic drug based on an original ANDA.
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: Community and Familial Impacts of the Opioid Crisis
A completed clinical trial examining the community and family impacts of the opioid crisis. It addresses issues related to opioid use disord…
-
CLINICAL_TRIALS trial_result · 2025-07-03Clinical Trial Update: Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg [Phase 1]
Phase 1 pharmacodynamic study evaluating an intramuscular nalmefene autoinjector (1.5 mg) versus intranasal naloxone (Narcan) 4 mg for opioi…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: The Feasibility of Using the PulsePoint to Facilitate Overdose Education and Naloxone Distribution [NA]
This clinical trial update reports on the feasibility of using the PulsePoint platform to facilitate overdose education and naloxone distrib…
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: UnityPhilly Response App for Overdose Reversal
Drexel University-sponsored clinical trial evaluating the UnityPhilly Response App for opioid overdose reversal is currently not recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-06-12EMA Authorised: Nyxoid (naloxone hydrochloride dihydrate) — Mundipharma Corporation (Ireland) Limited
EMA has authorised Nyxoid (naloxone hydrochloride dihydrate) for the emergency treatment of opioid overdose. The product is manufactured by …
-
FDA approval · 2025-06-04FDA Approved: NALOXONE HYDROCHLORIDE — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for naloxone hydrochloride submitted by Par Health USA, LLC.
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: Improving Access to Naloxone to Prevent Opioid Overdose Deaths (SAIA-Naloxone) [NA]
This clinical trials registry entry updates the SAIA-Naloxone trial (NCT05886712) sponsored by RTI International, which aims to improve acce…
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal [Phase 2]
Phase 2 trial evaluating inhaled cannabis (vaped marijuana) to attenuate naloxone-precipitated withdrawal in the context of opioid overdose;…
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: Naloxone for Opioid Associated Out of Hospital Cardiac Arrest [Phase 2]
Phase 2 clinical trial evaluating Naloxone for opioid-associated out-of-hospital cardiac arrest. Recruitment has not yet begun.
-
CLINICAL_TRIALS withdrawal · 2025-02-10Clinical Trial Update: Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose [Phase 3]
A Phase 3 trial comparing nalmefene to naloxone for recurrent respiratory depression after opioid overdose has been withdrawn from the study…
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Peer Intervention to Link Overdose Survivors to Treatment (PILOT) [NA]
The PILOT trial evaluating a peer-intervention approach to connect opioid overdose survivors to treatment has completed and results have bee…
-
FDA approval · 2025-01-16FDA Approved: NALOXONE HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for a generic naloxone hydrochloride product by Mylan Institutional LLC.
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Preventing Opioid Overdose Mortality in the United States [NA]
A completed clinical trial evaluating strategies to prevent opioid overdose deaths in the United States has posted results.
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: Serious Game to Teach Opioid Overdose Response [Phase 2]
A Phase 2 study sponsored by the University of Nevada, Reno is evaluating a serious game to teach opioid overdose response; the trial is not…
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program [NA]
A multi-center randomized controlled trial evaluating NYC's Relay Nonfatal Overdose Response Program; results from the completed study have …
-
FDA approval · 2024-11-05FDA Approved: NALOXONE HYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories, Inc.)
FDA approved a supplemental application for naloxone hydrochloride submitted by Dr. Reddy's Laboratories, Inc.
-
FDA approval · 2024-11-02FDA Approved: NALOXONE HYDROCHLORIDE — Supplemental Application (BPI Labs LLC)
FDA approved a supplemental application for Naloxone hydrochloride submitted by BPI Labs LLC. This action confirms approval of an additional…
-
CLINICAL_TRIALS withdrawal · 2024-11-01Clinical Trial Update: Blood Naloxone Levels Following Intradermal Injection in Humans [Phase 4]
The Phase 4 trial evaluating intradermal naloxone for opioid overdose has been withdrawn; no recruitment or results are reported.
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: FAVOR Opioid Recovery Coaching Evaluation [NA]
The FAVOR Opioid Recovery Coaching Evaluation trial has completed; it examines a recovery coaching approach for opioid-use disorder and rela…
-
CLINICAL_TRIALS research · 2024-10-17Clinical Trial Update: Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
This clinical trial update from Kaiser Permanente examines how health insurance instability affects mortality among patients receiving bupre…
-
FDA approval · 2024-08-28FDA Approved: NALOXONE HYDROCHLORIDE — Supplemental Application (Baxter Healthcare Corporation)
FDA approved Baxter Healthcare Corporation's supplemental application for naloxone hydrochloride, a generic opioid overdose reversal agent, …
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of CSX-1004 [Phase 1]
Phase 1 study of CSX-1004 reports safety, tolerability, and pharmacokinetics in participants with opioid overdose or opioid use disorder; th…
-
FDA approval · 2024-08-13FDA Approved: NALOXONE HYDROCHLORIDE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Naloxone Hydrochloride by Hospira, Inc., under ANDA070256.
-
CLINICAL_TRIALS trial_result · 2024-08-12Clinical Trial Update: Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder [NA]
Completed clinical trial evaluating a naloxone auto-injector as a universal precaution for patients with opioid use disorder; results were p…